{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:43:37Z","timestamp":1770983017235,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1423,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1998,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Many patients who present with dyspepsia are prescribed antacid\/alginates as their first line and often mainstay therapy. This multicentre study was designed to assess whether early introduction of acid inhibition is an effective strategy in dyspepsia management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Dyspeptic patients (<jats:italic>n<\/jats:italic>\u2003=\u2003674) were randomized to receive either omeprazole 10\u2003mg o.m. or antacid\/alginate liquid 10\u2003mL q.d.s. for 4\u2003weeks in an open, parallel group study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Complete relief of the most common symptom at entry, heartburn, was greater in the omeprazole\u2010treated group compared with the antacid\/alginate\u2010treated group (64 vs. 30%, respectively, at 4\u2003weeks; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). The percentage of patients who met the stringent health target of complete relief of overall symptoms was higher in the omeprazole\u2010treated group (41% at 4\u2003weeks) compared with the antacid\/alginate group (16% at 4\u2003weeks; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). Comparisons of quality of life scores between treatments favoured the omeprazole group at 2 and 4\u2003weeks for both the Psychological General Well\u2010Being Index and the Gastrointestinal Symptom Rating Scale (each <jats:italic>P<\/jats:italic>\u2003\u2264\u20030.0009). In addition, a greater proportion of patients rated omeprazole to be more effective in symptom relief and more convenient to use (each <jats:italic>P<\/jats:italic>\u2003=\u20030.0001) than antacid\/alginate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrates that, compared to antacid\/alginate liquid 10\u2003mL q.d.s., omeprazole 10\u2003mg o.m. is more effective in the management of dyspepsia symptoms and is the patients\u2019 preferred treatment.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1998.0284f.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:36:03Z","timestamp":1047353763000},"page":"147-157","source":"Crossref","is-referenced-by-count":47,"title":["First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid\/alginate liquid: a multicentre study in general practice"],"prefix":"10.1111","volume":"12","author":[{"family":"Goves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Oldring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Dallara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Roffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"145","article-title":"Functional dyspepsia: A classification with guidelines for diagnosis and management","volume":"4","author":"Talley NJ","year":"1991","journal-title":"Gastroenterol Int"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529309101568"},{"key":"e_1_2_6_4_2","first-page":"47","article-title":"Prevalence of symptoms of dyspepsia in the community","volume":"1","author":"Jones R","year":"1989","journal-title":"Lancet"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.31.4.401"},{"key":"e_1_2_6_6_2","first-page":"1136","article-title":"Endoscopic studies of dyspepsia in a general practice","volume":"1","author":"Gear MWL","year":"1989","journal-title":"Br Med J"},{"key":"e_1_2_6_7_2","first-page":"6","article-title":"Upper gastrointestinal endoscopy\u2014a view from general practice","volume":"36","author":"Jones R","year":"1986","journal-title":"J R Coll Gen Pract"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90879-3"},{"key":"e_1_2_6_9_2","unstructured":"ForresterE.Alternative advice on dyspepsia treatment.Gastroenterol Pract1994; Feb\/Mar:67."},{"key":"e_1_2_6_10_2","unstructured":"HeatleyR.Dyspepsia: GP guide to drug management.Prescriber1995; 19 October:3950."},{"key":"e_1_2_6_11_2","unstructured":"CromptonB. Dyspepsia: A rational approach to management.Prescriber1995; 19 October:5256."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92023-0"},{"key":"e_1_2_6_13_2","first-page":"293","article-title":"Dyspepsia: Is a trial of therapy appropriate","volume":"153","author":"Thompson G","year":"1995","journal-title":"Can Med Assoc J"},{"key":"e_1_2_6_14_2","unstructured":"Dundee Dyspepsia Management Guidelines 1996."},{"key":"e_1_2_6_15_2","first-page":"119","article-title":"Cost\u2010effective management of dyspepsia","volume":"10","author":"Mucklow JC","year":"1996","journal-title":"Br J Med Econ"},{"key":"e_1_2_6_16_2","unstructured":"British Society of Gastroenterology. Guidelines in Gastroenterology 1: Dyspepsia Management Guidelines British Society of Gastroenterology September 1996."},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/014107688808100409","article-title":"Managing the dyspeptic patient: Experience of a single visit dyspepsia clinic","volume":"81","author":"Lobo A","year":"1988","journal-title":"J R Soc Med"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.3.422"},{"key":"e_1_2_6_19_2","first-page":"166","article-title":"Double\u2010blind clinical study of an alginate compound vs. ranitidine in patients with gastroesophageal reflux disease","volume":"9","author":"Porro GB","year":"1992","journal-title":"Adv Ther"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01298864"},{"key":"e_1_2_6_21_2","article-title":"Omeprazole 10\u2003mg or 20\u2003mg daily for the prevention of relapse in gastroesophageal reflux disease? A double\u2010blind comparative study","volume":"102","author":"Laursen LS","year":"1992","journal-title":"Gastroenterology"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528609090924"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1991.tb00532.x"},{"key":"e_1_2_6_24_2","unstructured":"DepuyHJ.The Psychological General Well\u2010Being (PGWB) Index. In: Wenger NK Mattson ME Furberg CD Elinsson J eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Le Jacq Publishing Inc. USA 1984:170183."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529309098272"},{"key":"e_1_2_6_26_2","unstructured":"GliseH.Measurement of the impact of heartburn and dyspepsia on Quality of Life. In: Proceedings Heartburn & Dyspepsia\u2014Diagnostic Challenge Healthcare Dilemma. Barcelona Spain 25th November 1995:3234."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6138.653"},{"key":"e_1_2_6_28_2","first-page":"29","article-title":"Is there such an entity as mild oesophagitis","volume":"4","author":"Green JRB","year":"1993","journal-title":"Eur J Clin Res"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8608881"},{"key":"e_1_2_6_30_2","article-title":"Effect of omeprazole in Helicobacter pylori","volume":"32","author":"Sharp J","year":"1991","journal-title":"Gut"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1991.tb00032.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.0284f.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.0284f.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1046\/j.1365-2036.1998.0284f.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T01:03:55Z","timestamp":1698541435000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1998.0284f.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,2]]}},"alternative-id":["10.1046\/j.1365-2036.1998.0284f.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1998.0284f.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,2]]}}}